-
China’s Antengene raises $120m to boost drug development
pharmaceutical-technology
January 03, 2019
Chinese biopharmaceutical firm Antengene has raised $120m in a series B funding round led by Boyu Capital and FountainVest to support the development and commercialisation of new therapeutics.
-
Lupin in partnership with AbbVie
en-cphi.cn
December 26, 2018
To develop and commercialise a novel oncology drug to treat haematological cancers
-
Orchard Therapeutics and SIRION Biotech Announce Licensing Agreement to Enhance Gene Therapy Manufacturing Efficiency
b3cnewswire
December 17, 2018
Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with......
-
Ablexis Announces Licensing Agreement with Allogene Therapeutics
americanpharmaceuticalreview
December 10, 2018
Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, has announced a license agreement....
-
EUSA Pharma Appoints President of US Operations
americanpharmaceuticalreview
December 06, 2018
EUSA Pharma, a global biopharmaceutical company with a focus on oncology and rare disease, has announced the appointment of Jeffrey S. Hackman as President.....
-
Open Health merges with med comms services provider Peloton
pharmaphorum
December 05, 2018
UK-based Open Health Communications has merged with Peloton Advantage to create a global healthcare communications and market access group.
-
Athenex Announces License Agreement with PharmaEssentia for Oradoxel (Oral Formulation of Docetaxel) in Several Areas in Asia
pharmafocusasia
December 03, 2018
Athenex, Inc., a global biopharmaceutical company dedicated to the research of new therapies for cancer and related diseases, Development and commercialization......
-
Immune Regulation Announces Positive Results from Phase 1 Clinical Trial of PIN201104
b3cnewswire
November 26, 2018
Study C1104-001 was a First Time in Human, randomised, double blind, placebo controlled, parallel group study in healthy volunteers and patients with asthma to assess the safety, tolerability and pharmacokinetics of single ascending and repeat doses of ‘1
-
New biopharmaceutical testing laboratory to open in Geneva
cphi-online
August 29, 2018
SGS's expansion will enable the service provider to offer a full ICH Q6B physico-chemical characterization of biological products.
-
Ligand Pharma readies $650M convertible debt offering
biospectrumasia
May 18, 2018
In connection with the offering of the notes, Ligand expects to grant the initial purchasers a 13-day option to purchase up to an additional $100 million aggregate principal amount of the notes, solely to cover overallotments, if any.